The most common risk factors for hyperkalemia are reduced kidney function and treatment with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. With evidence showing the increased risk of morbidity and mortality associated with hyperkalemia caused by stopping RAASi therapy, how can we best manage potassium abnormalities and protect our patients through optimized RAASi therapy? This panel discussion featuring Drs. George Bakris, Matthew Weir, and Faiez Zannad will highlight the latest tools for treating hyperkalemia as well as practice tips for its continued management while titrating RAASi therapy to the most effective levels.
